

Global Transthyretin Amyloidosis Treatment Market Segments, Driver, Restraints, And Trends

*The Business Research Company's
Transthyretin Amyloidosis Treatment
Global Market Report 2024 – Market Size,
Trends, And Global Forecast 2024-2033*

LONDON, GREATER LONDON, UK, June 25, 2024 /EINPresswire.com/ -- The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from \$5.07 billion in 2023 to \$5.52 billion in 2024

at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, and collaboration in research.



The Business
Research Company

Transthyretin Amyloidosis Treatment Global Market
Report 2024 : Market Size, Trends, And Global
Forecast 2024-2033

“

You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs
-The Business Research
Company”

*The Business Research
Company*

Rising Aging Population Drives Market Growth

The rising aging population demographic is expected to propel the growth of the transthyretin amyloidosis treatment market going forward. An aging population refers to a demographic shift in which the median age of a population increases due to declining fertility rates and rising life expectancy. Aging is a significant risk factor for transthyretin amyloidosis (ATTR), and as the population ages, there is a higher prevalence of Transthyretin Amyloidosis cases. This leads to a growing patient pool in

need of treatment. For instance, in October 2022, according to the World Health Organization, every country in the world is experiencing growth in both the size and proportion of older persons in the population, and by 2030, 1 in 6 people in the world will be aged 60 years or over. Therefore, the rising demographics of the aging population are driving the growth of the transthyretin amyloidosis treatment market.

Explore comprehensive insights into the global transthyretin amyloidosis treatment market with

a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=13129&type=smp

Key Players

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

Trends in Transthyretin Amyloidosis Treatment

Major companies in the transthyretin amyloidosis treatment market focus on developing innovative and specialized treatments, such as orphan drugs, to enhance patient outcomes and expand treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis condition, often receiving regulatory benefits to support its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval of a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, leading to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to mitigate the synthesis of transthyretin (TTR) protein to address both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022.

Segments:

The transthyretin amyloidosis treatment market covered in this report is segmented –

- 1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- 2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
- 3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
- 4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Geographical Insights: North America Leading the Market

North America was the largest region in the transthyretin amyloidosis treatment market in 2023. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access the complete report for an in-depth analysis of the global transthyretin amyloidosis treatment market:

<https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment->

[global-market-report](#)

Transthyretin Amyloidosis Treatment Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Transthyretin Amyloidosis Treatment Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on transthyretin amyloidosis treatment market size, transthyretin amyloidosis treatment market drivers and trends, transthyretin amyloidosis treatment market major players, competitors' revenues, market positioning, and market growth across geographies. The transthyretin amyloidosis treatment market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By [The Business Research Company](#):

Pediatric Bladder Treatment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report>

Mineral And Bone Disorder Treatment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report>

Neurotrophic Keratitis Treatment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/722661421>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.